The British Medicines Agency, the Medicines and Healthcare Products Regulatory Agency (MHRA), announced in a press release on Friday that it had authorized the oral treatment of COVID-19 developed by Pfizer in adults with mild to moderate forms of the disease and at risk of developing a severe form due to their medical history.
In view of the available data, the British regulator decided that this drug, called Paxlovid, was
safe and effective in reducing the risk of hospitalization and death in this population.
Paxlovid treatment combines a new active substance (PF-07321332) and ritonavir, an antiretroviral drug that has long been used in the treatment of HIV-AIDS, which blocks viral enzymes and therefore makes the drug more effective.
The treatment, which should be started as soon as possible, is in the form of two tablets (one for each active substance) to be taken orally twice a day for five days.
At this point, the MHRA explains that it is too early to know if this treatment works for COVID-19 resulting from contamination with the Omicron variant, but specifies that it is working proactively with the American laboratory to determine if it is. is the case.
Paxlovid was cleared last week by the US Food and Drug Administration (FDA) and is under continuous evaluation
rolling review by the European Medicines Agency.